"HM Puerta del Sur es un hospital médico-quirúrgico y materno-infantil dotado de la última innovación tecnológica y con la cartera de servicios más amplia destinada a dar servicio a la zona sur de Madrid. Con 25.000 m2, el hospital dispone de todas las especialidades médico-quirúrgicas, tanto de niños como de adultos, y Urgencias las 24 horas. Cuenta con un Servicio de Diagnóstico por Imagen totalmente digitalizado y con el primer PET-RM de adquisición simultánea de España, que tiene integrado un PET de última generación. Complementando al PET-RMN se encuentra la primera instalación en España de un sistema de RMN–HIFU destinado al tratamiento de enfermedades neurológicas."

During the past decade, Hospital Universitario HM Puerta del Sur conducted 23 clinical trials. In the 10-year time frame, 23 clinical trials started and 1 clinical trials were completed, i.e. on average, 4.3% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 1 clinical trials were completed. i.e. 6.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hospital Universitario HM Puerta del Sur" #1 sponsor was "BioNTech SE" with 2 trials, followed by "Daiichi Sankyo, Inc." with 2 trials sponsored, "Fundación de investigación HM" with 2 trials sponsored, "InSightec" with 2 trials sponsored and "Janssen Research & Development, LLC" with 2 trials sponsored. Other sponsors include 8 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital Universitario HM Puerta del Sur" #1 collaborator was "Pfizer" with 2 trials as a collaborator, "Syntax for Science, S.L" with 2 trials as a collaborator, "Adknoma Health Research" with 1 trials as a collaborator, "Anavex Germany GmbH" with 1 trials as a collaborator and "AstraZeneca" with 1 trials as a collaborator. Other collaborators include 8 different institutions and companies that were collaborators in the rest 18 trials.

According to Clinical.Site data, the most researched conditions in "Hospital Universitario HM Puerta del Sur" are "Parkinson Disease" (3 trials), "COVID-19" (2 trials), "Covid-19" (2 trials), "Atrial Fibrillation" (1 trials) and "COVID" (1 trials). Many other conditions were trialed in "Hospital Universitario HM Puerta del Sur" in a lesser frequency.

Most popular intervention types in "Hospital Universitario HM Puerta del Sur" are "Drug" (14 trials), "Biological" (5 trials), "Device" (4 trials) and "Other" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Accordion Pill™ Carbidopa/Levodopa" (1 trials), "BNT162b2" (1 trials), "BNT162b2 20mcg" (1 trials) and "BNT162b2 30mcg" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hospital Universitario HM Puerta del Sur" are 19 trials for "All" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "Hospital Universitario HM Puerta del Sur". undefined are not yet recruiting, 3 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Hospital Universitario HM Puerta del Sur, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Hospital Universitario HM Puerta del Sur, 0 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 4 trials that are defined as “Not Applicable".